文献速递白血病

ATP1A1/BCL2L1可预测粒单核细胞和单核细胞急性髓系白血病对强心苷的反应

ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.
PubMed 文献 · Leukemia · 2023-10-30

粒单核细胞和单核细胞急性髓系白血病(AML)亚型对以维奈克拉为基础的方案存在固有耐药。本研究报道AML患者原始细胞体外对半合成强心苷UNBS1450的反应及细胞系体外敏感性与ATP1A1/BCL2L1表达比值相关。公共AML数据集显示粒单核/单核细胞分化是最稳健的预后特征,并涉及CBFB、KMT2A重排和FLT3错义突变。

要点

  • ATP1A1/BCL2L1表达比值与AML原始细胞对UNBS1450的体外反应相关。
  • 粒单核/单核细胞分化是AML数据集中最稳健的预后特征。
  • 体内强心苷总体耐受,对肿瘤生长影响从抑制到消退不等。

核心结论

  • ATP1A1/BCL2L1表达比值可能作为特定AML亚型中强心苷老药新用的预测标志物。

研究设计与样本

  • 研究检测AML患者原始细胞体外对半合成强心苷UNBS1450的反应及已建立细胞系的体外敏感性。
  • 利用公共可获取的AML数据集分析与反应相关的预后特征。
  • 体内评估强心苷的耐受性和对肿瘤生长的影响。

主要发现

  • AML患者原始细胞体外反应和细胞系体外敏感性与ATP1A1/BCL2L1表达比值相关。
  • 公共AML数据集显示粒单核/单核细胞分化是最稳健的预后特征,并与CBFB、KMT2A重排和FLT3错义突变相关。
  • 机制上BCL2L1保护细胞免于强心苷介导的逐步离子扰动、蛋白合成抑制和MCL1下调所诱导的细胞死亡。
  • 体内强心苷总体耐受,对肿瘤生长影响从肿瘤生长抑制到消退不等。

关键数值与推荐

  • 体外反应与ATP1A1/BCL2L1表达比值相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelomonocytic and monocytic acute myeloid leukemia (AML) subtypes are intrinsically resistant to venetoclax-based regimens. Identifying targetable vulnerabilities would limit resistance and relapse. We previously documented the synergism of venetoclax and cardiac glycoside (CG) combination in AML. Despite preclinical evidence, the repurposing of cardiac glycosides (CGs) in cancer therapy remained unsuccessful due to a lack of predictive biomarkers. We report that the ex vivo response of AML patient blasts and the in vitro sensitivity of established cell lines to the hemi-synthetic CG UNBS1450 correlates with the ATPase Na+/K+ transporting subunit alpha 1 (ATP1A1)/BCL2 like 1 (BCL2L1) expression ratio. Publicly available AML datasets identify myelomonocytic/monocytic differentiation as the most robust prognostic feature, along with core-binding factor subunit beta (CBFB), lysine methyltransferase 2A (KMT2A) rearrangements, and missense Fms-related receptor tyrosine kinase 3 (FLT3) mutations. Mechanistically, BCL2L1 protects from cell death commitment induced by the CG-mediated stepwise triggering of ionic perturbation, protein synthesis inhibition, and MCL1 downregulation. In vivo, CGs showed an overall tolerable profile while impacting tumor growth with an effect ranging from tumor growth inhibition to regression. These findings suggest a predictive marker for CG repurposing in specific AML subtypes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cerella C, Gajulapalli SR, Lorant A, et al. ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides. Leukemia. 2023. PMID: 37904054. doi:10.1038/s41375-023-02076-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。